サンプル依頼リスト カート
  • English
市場調査レポート
商品コード
1226850

欧州の肺動脈性肺高血圧症市場の2028年までの予測- 地域別分析- 薬剤別、タイプ別、投与経路別、流通チャネル別

Europe Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Drugs, Type, Route of Administration, and Distribution Channel
出版日: | 発行: The Insight Partners | ページ情報: 英文 148 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
欧州の肺動脈性肺高血圧症市場の2028年までの予測- 地域別分析- 薬剤別、タイプ別、投与経路別、流通チャネル別
出版日: 2023年02月10日
発行: The Insight Partners
ページ情報: 英文 148 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧州の肺動脈性性肺高血圧症市場は、2022年の19億5,947万米ドルから2028年には26億8,307万米ドルに成長すると予測され、2022年から2028年までのCAGRは5.4%と推定されています。

肺動脈性肺高血圧症の発症率の増加が欧州の肺動脈性性肺高血圧症市場を牽引

肺動脈性肺高血圧症（PAH）は、肺の細い動脈に影響を与え、太く狭くなり、肺を通る血流が遮断されます。その結果、肺の血圧が上昇し、心臓は狭くなった動脈から血液を送り出すのに困難に直面します。やがて、心臓は全身に血液を効率よく送り出す能力を失っていきます。PAHは通常、30～60歳の女性に発症します。さらに、2019年に発表されたEuropean Respiratory Reviewの論文によると、PAHの発症率はスコットランドで100万人あたり7.6件となっています。家族歴や特定された危険因子が存在する特発性PAHはさらにまれで、スコットランドでは100万人あたり2.6人の症例を記録しています。このように、肺動脈性肺高血圧症の発生率の増加が、欧州の肺動脈性肺高血圧症市場の成長を牽引しています。

欧州の肺動脈性肺高血圧症市場の概要

欧州の肺動脈性肺高血圧症市場は、ドイツ、英国、フランス、イタリア、スペイン、その他欧州に区分されます。この地域は、世界の肺動脈性肺高血圧症市場において大きな市場シェアを占めています。欧州の肺動脈性肺高血圧症市場は、製品承認の増加により、予測期間中に大きな成長を遂げることが期待されています。肺動脈性肺高血圧症は、英国では約20,000人に1人が罹患する稀な疾患です。2021年には、英国で7,876人が肺高血圧症に罹患しています。英国では、特発性肺動脈性肺高血圧症（IPAH）を患う若年層の患者さんの5年生存率は80％を超えています。英国では、PAHとCTEPH（肺血管系の変化が直接の原因となって起こる病気）に苦しむ患者さんは、国内にある9つの専門センターで最もよく治療を受けています。英国のPulmonary Hypertension Association UK（PHA-UK）は、肺高血圧症に罹患した人々のために専ら提唱しています。したがって、このような取り組みが、予測期間中、同国の肺動脈性肺高血圧症治療薬市場を後押しすると期待されています。

欧州の肺動脈性性肺高血圧症治療薬市場の収益と2028年までの予測

欧州の肺動脈性性肺高血圧症薬市場のセグメンテーション

欧州の肺動脈性肺高血圧症市場は、薬剤、タイプ、投与経路、流通チャネル、国に基づいてセグメント化されます。

薬剤に基づき、欧州の肺動脈性性肺高血圧症市場は、エンドセリン受容体拮抗薬（ERA）、プロスタサイクリンおよびプロスタサイクリン類似体、sGC刺激薬、pde-5ディップスティックに区分されます。2022年、プロスタサイクリンおよびプロスタサイクリンアナログセグメントは、欧州の肺動脈性性肺高血圧症市場で最大のシェアを記録しました。

タイプに基づき、欧州の肺動脈性性肺高血圧症市場はブランド品とジェネリック医薬品に二分されます。2022年、欧州の肺動脈性性肺高血圧症市場では、ブランド品がより大きなシェアを記録しました。

投与経路に基づき、欧州の肺動脈性性肺高血圧症市場は、経口、静脈内/皮下、吸入に区分されます。2022年、欧州の肺動脈性性肺高血圧症市場では、経口投与セグメントが最大のシェアを記録しました。

流通チャネルに基づき、欧州の肺動脈性性肺高血圧症市場は、病院薬局・クリニック、オンライン薬局、小売薬局に区分されます。2022年には、病院薬局・診療所セグメントが欧州の肺動脈性性肺高血圧症市場で最大のシェアを記録しました。

国別に見ると、欧州の肺動脈性肺高血圧症市場は、英国、ドイツ、フランス、イタリア、スペイン、その他欧州に区分されます。2022年、英国は欧州の肺動脈性性肺高血圧症市場において最大のシェアを登録しました。

Bayer AG、Gilead Inc、GSK Plc、Johnson &Johnson、Lupin Ltd、Novartis AG、Pfizer Inc、Teva Pharmaceutical Industries Ltd、United Therapeutics Corpは、欧州の肺動脈性性肺高血圧症市場で活動している主要企業です。

目次

第1章 イントロダクション

第2章 欧州の肺動脈性性肺高血圧症市場-主要な要点

第3章 調査手法

  • カバレッジ
  • 2次調査
  • 1次調査

第4章 欧州の肺動脈性肺高血圧症市場- 市場情勢

  • 欧州PEST分析
  • 専門家の見解

第5章 欧州の肺動脈性性肺高血圧症市場- 主要市場力学

  • 市場促進要因
    • 肺動脈性肺高血圧症の罹患率の増加
  • 市場抑制要因
    • 肺動脈性肺高血圧症の治療に使用される薬剤の副作用
  • 市場機会
    • 特許切れ別ジェネリック医薬品の入手の困難化
  • 今後の動向
    • 肺動脈性肺高血圧症の治療薬開発のための臨床試験の増加
  • 影響分析

第6章 肺動脈性肺高血圧症市場- 欧州分析

  • 欧州の肺動脈性性肺高血圧症市場の収益予測と分析

第7章 欧州の肺動脈性性肺高血圧症市場-2028年までの収益と予測- 薬剤別

  • 欧州の肺動脈性性肺高血圧症市場の売上高シェア、薬剤別2021年・2028年（%）
  • エンドセリン受容体拮抗薬（ERAs）
  • プロスタサイクリンおよびプロスタサイクリンアナログ
  • SGC刺激剤
  • Pde-5ディップスティック

第8章 欧州の肺動脈性性肺高血圧症の市場分析と2028年までの予測- タイプ別

  • 欧州の肺動脈性性肺高血圧症市場、タイプ別2021年・2028年（%）
  • ブランド品
  • ジェネリック医薬品

第9章 欧州の肺動脈性性肺高血圧症市場-2028年までの収益と予測- 投与経路別

  • 欧州の肺動脈性性肺高血圧症市場収入シェア：投与経路別2021年・2028年（%）
  • 経口
  • 静脈内/皮下
  • 吸入投与

第10章 欧州の肺動脈性性肺高血圧症市場-2028年までの収益と予測- 流通チャネル別

  • 欧州の肺動脈性性肺高血圧症市場売上高シェア：流通チャネル別2021年・2028年（%）
  • 病院の薬局・診療所
  • オンライン薬局
  • 小売薬局

第11章 欧州の肺動脈性性肺高血圧症市場-2028年までの収益と予測- 国別分析

  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • その他欧州

第12章 肺動脈性肺高血圧症市場- 業界情勢

  • 有機的開発
  • 無機的展開

第13章 企業プロファイル

  • Johnson & Johnson
  • Gilead Sciences Inc
  • United Therapeutics Corp
  • Bayer AG
  • Novartis AG
  • GSK Plc
  • Teva Pharmaceutical Industries Ltd
  • Lupin Ltd
  • Pfizer Inc

第14章 付録

図表

List Of Tables

  • Table 1. Europe Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 2. UK Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 3. UK Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 4. UK Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 5. UK Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 6. Germany Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 7. Germany Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 8. Germany Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 9. Germany Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 10. France Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 11. France Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 12. France Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 13. France Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 14. Italy Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 15. Italy Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 16. Italy Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 17. Italy Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 18. Spain Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 19. Spain Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 20. Spain Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 21. Spain Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 22. Rest of Europe Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 23. Rest of Europe Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 24. Rest of Europe Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 25. Rest of Europe Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 26. Organic Developments in the Europe pulmonary arterial hypertension market
  • Table 27. Inorganic Developments in the Europe pulmonary arterial hypertension market
  • Table 28. Glossary of Terms

List Of Figures

  • Figure 1. Europe Pulmonary Arterial Hypertension Market Segmentation
  • Figure 2. Europe Pulmonary Arterial Hypertension Market - By Country
  • Figure 3. Europe Pulmonary Arterial Hypertension Market Overview
  • Figure 4. Prostacyclin and Prostacyclin Analogs Segment Held Largest Share by Drugs of the Europe Pulmonary Arterial Hypertension Market
  • Figure 5. UK to Show Significant Growth During Forecast Period
  • Figure 6. Europe: PEST Analysis
  • Figure 7. Experts Opinion
  • Figure 8. Europe Pulmonary Arterial Hypertension Market Impact Analysis of Drivers and Restraint
  • Figure 9. Europe Pulmonary Arterial Hypertension Market- Revenue Forecast and Analysis - 2020 - 2028
  • Figure 10. Europe Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
  • Figure 11. Endothelin Receptor Antagonists (ERAs): Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 12. Prostacyclin and Prostacyclin Analogs: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 13. sGC Stimulators: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 14. Pde-5 Dipsticks: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 15. Europe Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
  • Figure 16. Branded: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 17. Generics: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 18. Europe Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
  • Figure 19. Oral: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 20. Intravenous/ Subcutaneous: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 21. Inhalational: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 22. Europe Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
  • Figure 23. Hospital Pharmacies and Clinics: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 24. Online Pharmacies: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 25. Retail Pharmacies: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 26. Europe: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 27. Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
  • Figure 28. UK: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 29. Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 30. France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 31. Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 32. Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 33. Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
目次
Product Code: BMIRE00028023

The Europe pulmonary arterial hypertension market is expected to grow from US$ 1,959.47 million in 2022 to US$ 2,683.07 million by 2028; it is estimated to grow at a CAGR of 5.4% from 2022 to 2028.

Growing Incidence of Pulmonary Arterial Hypertension Drives Europe Pulmonary Arterial Hypertension Market

Pulmonary arterial hypertension (PAH) affects the tiny arteries in the lung, making it thick and narrow and blocking the blood flow through the lungs. As a result, blood pressure in the lungs increases, and the heart faces difficulties in pumping blood through narrowed arteries. Over time, an individual's heart loses the ability to pump blood throughout the body effectively. PAH usually affects women between the ages of 30 and 60. Further, according to an article in European Respiratory Review published in 2019, the incidence of PAH is 7.6 cases per million in Scotland. Idiopathic PAH-in which a family history or an identified risk factor is present-is even rare, recording 2.6 cases per million in Scotland. Thus, the growing incidence of pulmonary arterial hypertension is driving the growth of the Europe pulmonary arterial hypertension market.

Europe Pulmonary Arterial Hypertension Market Overview

The Europe pulmonary arterial hypertension market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the global pulmonary arterial hypertension market. The Europe pulmonary arterial hypertension market is expected to witness significant growth during the forecast period due to a rise in product approvals. Pulmonary hypertension is a rare condition that affects approximately one in 20,000 people in the UK. In 2021, 7,876 individuals in the UK suffered from pulmonary hypertension. In the UK, younger patients suffering from idiopathic pulmonary arterial hypertension (IPAH) have a 5-year survival above 80%. In the UK, patients suffering from PAH and CTEPH (the disease is caused due to a direct consequence of changes in the pulmonary vasculature) are most commonly treated in nine specialist centers across the country. The Pulmonary Hypertension Association UK (PHA-UK) in the UK advocates exclusively for people affected by pulmonary hypertension. Therefore, such initiatives are expected to fuel the pulmonary arterial hypertension drug market in the country during the forecast period.

Europe Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US$ Billion)

Europe Pulmonary Arterial Hypertension Market Segmentation

The Europe pulmonary arterial hypertension market is segmented on the basis of drugs, type, route of administration, distribution channel, and country.

Based on drugs, the Europe pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. In 2022, the prostacyclin and prostacyclin analogs segment registered the largest share in the Europe pulmonary arterial hypertension market.

Based on type, the Europe pulmonary arterial hypertension market is bifurcated into branded and generics. In 2022, the branded segment registered a larger share in the Europe pulmonary arterial hypertension market.

Based on route of administration, the Europe pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. In 2022, the oral segment registered the largest share in the Europe pulmonary arterial hypertension market.

Based on distribution channel, the Europe pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. In 2022, the hospital pharmacies and clinics segment registered the largest share in the Europe pulmonary arterial hypertension market.

Based on country, the Europe pulmonary arterial hypertension market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. In 2022, the UK registered the largest share in the Europe pulmonary arterial hypertension market.

Bayer AG, Gilead Sciences Inc, GSK Plc, Johnson & Johnson, Lupin Ltd, Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, and United Therapeutics Corp are the leading companies operating in the Europe pulmonary arterial hypertension market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe pulmonary arterial hypertension market.
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the Europe pulmonary arterial hypertension market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the pulmonary arterial hypertension market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Europe Pulmonary Arterial Hypertension Market - By Drugs
    • 1.3.2 Europe Pulmonary Arterial Hypertension Market - By Type
    • 1.3.3 Europe Pulmonary Arterial Hypertension Market - By Route of Administration
    • 1.3.4 Europe Pulmonary Arterial Hypertension Market - By Distribution Channel
    • 1.3.5 Europe Pulmonary Arterial Hypertension Market - By Country

2. Europe Pulmonary Arterial Hypertension Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Pulmonary Arterial Hypertension Market - Market Landscape

  • 4.1 Overview
  • 4.2 Europe PEST Analysis
  • 4.3 Experts Opinion

5. Europe Pulmonary Arterial Hypertension Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Growing Incidence of Pulmonary Arterial Hypertension
  • 5.2 Market Restraints
    • 5.2.1 Side Effects of Drugs Used for Treatment of Pulmonary Arterial Hypertension
  • 5.3 Market Opportunities
    • 5.3.1 Availability of Generics at Affordable Costs Due to Growing Patent Expiration
  • 5.4 Future Trend
    • 5.4.1 Rising Clinical Trials for Drugs Development to Treat Pulmonary Arterial Hypertension
  • 5.5 Impact analysis

6. Pulmonary Arterial Hypertension Market - Europe Analysis

  • 6.1 Europe Pulmonary Arterial Hypertension Market Revenue Forecast and Analysis

7. Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Drugs

  • 7.1 Overview
  • 7.2 Europe Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
  • 7.3 Endothelin Receptor Antagonists (ERAs)
    • 7.3.1 Overview
    • 7.3.2 Endothelin Receptor Antagonists (ERAs): Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Prostacyclin and Prostacyclin Analogs
    • 7.4.1 Overview
    • 7.4.2 Prostacyclin and Prostacyclin Analogs: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.5 SGC Stimulators
    • 7.5.1 Overview
    • 7.5.2 sGC Stimulators: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.6 Pde-5 Dipsticks
    • 7.6.1 Overview
    • 7.6.2 Pde-5 Dipsticks: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

8. Europe Pulmonary Arterial Hypertension Market Analysis and Forecasts to 2028 - by Type

  • 8.1 Overview
  • 8.2 Europe Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
  • 8.3 Branded
    • 8.3.1 Overview
    • 8.3.2 Branded: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Generics
    • 8.4.1 Overview
    • 8.4.2 Generics: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

9. Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Route of Administration

  • 9.1 Overview
  • 9.2 Europe Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
  • 9.3 Oral
    • 9.3.1 Overview
    • 9.3.2 Oral: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.4 Intravenous/ Subcutaneous
    • 9.4.1 Overview
    • 9.4.2 Intravenous/ Subcutaneous: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.5 Inhalational
    • 9.5.1 Overview
    • 9.5.2 Inhalational: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

10. Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Distribution Channel

  • 10.1 Overview
  • 10.2 Europe Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
  • 10.3 Hospital Pharmacies and Clinics
    • 10.3.1 Overview
    • 10.3.2 Hospital Pharmacies and Clinics: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.4 Online Pharmacies
    • 10.4.1 Overview
    • 10.4.2 Online Pharmacies: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.5 Retail Pharmacies
    • 10.5.1 Overview
    • 10.5.2 Retail Pharmacies: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

11. Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - Country Analysis

  • 11.1 Europe: Pulmonary Arterial Hypertension Market
    • 11.1.1 Overview
    • 11.1.2 Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
      • 11.1.2.1 UK: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.1.1 Overview
        • 11.1.2.1.2 UK: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.1.3 UK: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.2.1.4 UK: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.2.1.5 UK: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.2.1.6 UK: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.1.2.2 Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.2.1 Overview
        • 11.1.2.2.2 Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.2.3 Germany: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.2.2.4 Germany: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.2.2.5 Germany: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.2.2.6 Germany: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.1.2.3 France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.3.1 Overview
        • 11.1.2.3.2 France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.3.3 France: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.2.3.4 France: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.2.3.5 France: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.2.3.6 France: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.1.2.4 Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.4.1 Overview
        • 11.1.2.4.2 Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.4.3 Italy: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.2.4.4 Italy: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.2.4.5 Italy: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.2.4.6 Italy: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.1.2.5 Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.5.1 Overview
        • 11.1.2.5.2 Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.5.3 Spain: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.2.5.4 Spain: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.2.5.5 Spain: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.2.5.6 Spain: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.1.2.6 Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.6.1 Overview
        • 11.1.2.6.2 Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.6.3 Rest of Europe: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.2.6.4 Rest of Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.2.6.5 Rest of Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.2.6.6 Rest of Europe: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)

12. Pulmonary Arterial Hypertension Market - Industry Landscape

  • 12.1 Overview
  • 12.2 Organic Developments
    • 12.2.1 Overview
  • 12.3 Inorganic Developments
    • 12.3.1 Overview

13. Company Profiles

  • 13.1 Johnson & Johnson
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Gilead Sciences Inc
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 United Therapeutics Corp
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Bayer AG
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Novartis AG
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 GSK Plc
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Teva Pharmaceutical Industries Ltd
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Lupin Ltd
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Pfizer Inc
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms